Cargando…
QTc Prolongation in SARS-CoV-2 (COVID-19) Patients Receiving Hydroxycloroquine: A Retrospective Study
Background and Aims Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has infected more than 153 million people and led to the death of 3.3 million others. The absence of an effective treatment other than vaccination, has led clinicians in the beginning t...
Autores principales: | Vlachopoylou, M., Hamissa, E.M., AbdAlgaffar, S.A., Chatzis, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Mosby, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556499/ http://dx.doi.org/10.1016/j.ahj.2021.10.018 |
Ejemplares similares
-
COVID 19 and the Systematic Use of Aspirin in Diabetics During Hospitalization: A Retrospective Study
por: Vlachopoylou, M., et al.
Publicado: (2021) -
Cardio-metabolic factors associated to mortality in patients with COVID-19
por: Eduardo, Camey, et al.
Publicado: (2022) -
Chloroquine/hydroxycloroquine and COVID-19: need to know more about
por: Cassone, Antonio, et al.
Publicado: (2020) -
QTc Prolongation in Patients Receiving Triazoles and Amiodarone
por: Cook, Katherine, et al.
Publicado: (2017) -
QTc interval prolongation in patients infected with SARS-CoV-2 and treated with antiviral drugs()()
por: Esmel-Vilomara, Roger, et al.
Publicado: (2022)